Some were concerned about increased imaging and interpretation times associated with DBT.
Adopting digital breast tomosynthesis (DBT) is not associated with a decrease in screening mammography capacity, according to a study published in the American Journal of Roentgenology.
Researchers from several states sought to determine whether adoption of DBT was associated with a decrease in screening mammography capacity across Breast Cancer Screening Consortium facilities, given concerns about increasing imaging and interpretation times associated with DBT.
The researchers collected facility characteristics and examination volume data from Breast Cancer Screening Consortium facilities that adopted DBT between 2011 and 2014. They evaluated differences between monthly screening volumes during the 12-month preadoption period and the 12-month postadoption period (with the two periods separated by a 3-month lag) and tested for changes in month-to-month facility-level screening volume during the preadoption and postadoption periods.
Related article: DBT Better Detects Cancer in Dense Breasts
The results showed that across five regional breast imaging registries, 15 of 83 facilities (18.1%) adopted DBT for screening between 2011 and 2014.
Facility-level monthly screening volumes were slightly higher during the postadoption versus preadoption periods. Monthly screening volumes remained relatively stable within the preadoption period and the postadoption period.
The researchers concluded that in a cohort of facilities with varied characteristics, monthly screening examination volumes did not decrease after DBT adoption.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.